Zoë S. Walters

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Charlotte Pawlyn, Michael D. Bright, Amy Buros et al. · Blood Cancer Journal · 2017 · 107 citations · Full text

Medicine, Molecular Biology, Oncology +17

JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells

Zoë S. Walters, Barbara Villarejo-Balcells, David Olmos et al. · Oncogene · 2013 · 105 citations · Full text

Life Sciences, Molecular Biology, Oncology +13

8-Substituted Pyrido[3,4-<i>d</i>]pyrimidin-4(3<i>H</i>)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors

Vassilios Bavetsias, Rachel M. Lanigan, G.F. Ruda et al. · Journal of Medicinal Chemistry · 2016 · 98 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy

Roberto Tonelli, Alan McIntyre, Consuelo Camerin et al. · Clinical Cancer Research · 2011 · 90 citations

Medicine, Cancer Biology, Oncology +17

The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)

Roberta Ciarapica, Maria De Salvo, Elena Carcarino et al. · Oncogene · 2013 · 71 citations · Full text

Life Sciences, Genetics, Molecular Biology +17